Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc. INM

InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology, Orofacial Pain, Glaucoma, ocular, CNS, respiratory, metabolic diseases, and others.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: The worst 1st half for stocks in decades
Gains in crude prices pushed futures for Canada’s main stock index higher on Monday although recession fears continued to weigh on sentiment.Canada’s competition bureau said that Rogers Communicat... read article.

Hottest Cannabinoids

https://www.benzinga.com/amp/content/27358332  rate and reply
@ the Bell: Energy & mining recover to lift TSX
Following a nasty session in the red, Canada’s main stock index rose more than 300 points in Friday trading. Gains were led by the energy and base metal sectors.After two brutal weeks brought... read article.

InMed Bezinga

https://youtu.be/rtssMjZ39lI  rate and reply
Buzz on the Bullboards: Another summer of uncertainty?
In times of uncertainty in the markets, investors tend to focus on more consistent plays.Not all investors are basking in summer vacations and backyard barbeques. For those who are still plugged... read article.

Cronos and Gingko

InMed is way away of these guys d9 THCV, the more pure form of THCV. https://financialpost.com/globe-newswire/cronos-group-and-ginkgo-bioworks-announce-achievement-of-thcv-equity-milestone  rate and reply

Cannabinoid Trial Results

https://www.theleafonline.com/c/health-wellness/2022/06/breaking-news-historys-largest-cannabinoid-trial-on-pain-finds-significant-improvement/  rate and reply

Oversold Conditions

https://finviz.com/quote.ashx?t=INM  rate and reply

Peer Reciewed Study Publication

https://financialpost.com/globe-newswire/inmed-announces-publication-of-peer-reviewed-study-highlighting-potential-role-of-rare-cannabinoids-thcv-cbc-and-others-on-skin-conditions  rate and reply

New Press Release - InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific study entitled...read article.

InMed Headlines

https://www.schaeffersresearch.com/content/news/2022/06/10/this-weeks-cannabis-stock-news-7-companies-make-headlines  rate and reply

Delta 9 THCV Study

Radicle Science is testing InMed's D9 THCV on 900 subjects right now. For those interested in scientific studies, a study from 2011 show positive results for: PTSD, panic and anxiety, Parkinson...read more

THCV launch

https://thedalesreport.com/cannabis/inmed-launches-thcv-expanding-its-portfolio-of-rare-cannabinoids-for-the-health-and-wellness-sector/  rate and reply

Excellent YT analysis on InMed Pharmaceuticals

https://youtu.be/YR3whoRE5lg  rate and reply

InMed Launches THCV!!!! Great News

Now we're cooking with gas! Some say Delta 9 THCV is the next CBD.  rate and reply

New Press Release - InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoid Bolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has been researched for a variety of potential benefits VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) -- InMed...read article.

🔺️9 THCV Cost

Right now, 9 THCV is sells for approximately 30K per kilo. https://www.pharmabinoid.eu/products/d9-tetrahydrocannabivarin-thcv  rate and reply

Radicle Science Study

Something to keep an eye on in the next few months. Delta 9 THCV to be taken by 900 participants in June and study results could be out as soon as July. Expecting commercial launch of delta 9 THCV...read more

THCV Release?

InMed stated that 4 cannabinoids would be ready for commercial sales within the first 6 months of the year. Still waiting for THCV announcement.  rate and reply

New Press Release - InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the closing of its previously announced registered...read article.

Bottom is In

Secured financials for +1 year, probably more since sales are stepping up in coming quaerters in parallell with new launches. - EB update very soon - insiders been adding recently, including CEO...read more

Big Pharma and Synthetic Cannabinoids

https://big-pharma-and-synthetic-cannabis/  rate and reply

Synthetic THC

https://www.axios.com/local/richmond/2022/06/03/virginia-lawmakers-approve-synthetic-thc-product-sales  rate and reply